A Phase 1 Open-label, 2-Period Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of BMS-986256 in Healthy Participants
Latest Information Update: 25 Jan 2022
At a glance
- Drugs Afimetoran (Primary) ; Famotidine (Primary)
- Indications Cutaneous lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 19 Dec 2021 Status changed from not yet recruiting to completed.
- 09 Nov 2021 Results assessing pharmacokinetics and safety of BMS-986256 in healthy subjects, presented at the ACR Convergence 2021.
- 06 Jul 2021 New trial record